MedPath

'Smart Reminder': a Feasibility Pilot Study on the Effects of a Wearable Device Treatment

Not Applicable
Completed
Conditions
Stroke
Registration Number
NCT05878132
Lead Sponsor
The Hong Kong Polytechnic University
Brief Summary

This pilot study examines the feasibility and potential effects on upper limb (UL) motor function using a wearable device integrated with a telerehabilitation function in the home setting with chronic stroke survivors.

The study seeks to address the question:

- Is wearable device intervention more effective in promoting arm recovery in stroke survivors than conventional therapy for home-based training? We hypothesize that using a multimodal feedback system in the wearable device can provide more effective training to improve the hemiplegic UL function of chronic stroke survivors than conventional therapy.

This is a single-blinded randomized crossover pilot trial. Twelve participants will be randomly assigned into two groups: the experimental (wristwatch) and the control (conventional therapy) groups. Participants in the experimental group will undergo a 4-week wearable device treatment followed by a 4-week conventional training.

Participants in the control group will complete conventional therapy and then wearable device treatment. There will be a 3-week washout period between treatments. Upper limb motor outcome measures will be evaluated at the following intervals: baseline, post-treatment at 4-week, after a 3-week washout period for pre-intervention, and post-intervention after crossover by research assistants blinded to group allocation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • age ≥ 18 years
  • unilateral hemispherical involvement
  • diagnosis of stroke with onset ≥ three months
  • hemiplegic upper limb with Functional test for hemiplegic upper extremity-Hong Kong version (FTHUE-HK) ≥ score of 3 (maximum of 7) (Fong et al., 2004).
  • no complaint of excessive pain and swelling over the hemiplegic arm
  • able to provide informed consent to participate.
Exclusion Criteria
  • participating in another similar form of experimental study during the same period
  • having a history of botulinum toxin injection in the past three months
  • having other significant upper limb impairment, i.e. fixed contractures, frozen shoulder, and severe arthritis
  • having a diagnosis which would interfere in the use of the device, i.e. visual impairment, active cardiac issues and palliative treatment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Change from baseline Motor Activity Log (MAL)Change from baseline at 4 weeks

The MAL is a self-reported questionnaire designed to assess how frequently and effectively patients utilize their affected arm daily. It consists of 2 subscales to measure patients' perceived amount of arm use (MAL-AOU) and quality of arm use (MAL-QOM) (Uswatte, Taub, Morris, Light \& Thompson, 2006)

Change from preintervention at 7-week (after crossover) Active range of motion (AROM) of shoulder and elbowChange from 7-week at 11 weeks

The active ROM of the shoulder (flexion) and elbow (flexion/ extension) will be evaluated using a manual goniometer.

Change from preintervention at 7-week (after crossover) Motor Activity Log (MAL)Change from 7-week at 11 weeks

The MAL is a self-reported questionnaire designed to assess how frequently and effectively patients utilize their affected arm daily. It consists of 2 subscales to measure patients' perceived amount of arm use (MAL-AOU) and quality of arm use (MAL-QOM) (Uswatte, Taub, Morris, Light \& Thompson, 2006)

Change from baseline Fugl Meyer Upper Extremity assessmentChange from baseline at 4 weeks

The FMA-UE is a 3-point scale with a maximum score of 66 that measures the synergistic pattern and ability to make arm movements.The total score is further subdivided into upper-extremity and hand subscores with a total score of 66 (Fugl Meyer et al., 1975)

Change from baseline Action Research Arm TestChange from baseline at 4 weeks

The ARAT is a frequently used assessment tool to assess hemiplegic upper limb function. It consists of 19 items comprising four domains: grasp, grip, pinch, and gross motor, and has a total score of 57 (Lyle, 1981).

Change from preintervention at 7-week (after crossover) Action Research Arm TestChange from 7-week at 11 weeks

The ARAT is a frequently used assessment tool to assess hemiplegic upper limb function. It consists of 19 items comprising four domains: grasp, grip, pinch, and gross motor, and has a total score of 57 (Lyle, 1981).

Change from baseline Active range of motion (AROM) of shoulder and elbowChange from baseline at 4 weeks

The active ROM of the shoulder (flexion) and elbow (flexion/ extension) will be evaluated using a manual goniometer.

Change from preintervention at 7-week (after crossover) Fugl Meyer Upper Extremity assessmentChange from 7-week at 11 weeks

The FMA-UE is a 3-point scale with a maximum score of 66 that measures the synergistic pattern and ability to make arm movements.The total score is further subdivided into upper-extremity and hand subscores with a total score of 66 (Fugl Meyer et al., 1975)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kenneth FONG

🇭🇰

Hong Kong, Hong Kong

Kenneth FONG
🇭🇰Hong Kong, Hong Kong

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.